VERONA PHARMA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.72 USD | 0.00% |
|
-0.51% | -20.93% |
Presentation Operator MessageOperator (Operator)Welcome to Verona Pharma's Third Quarter 2022 ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Verona Pharma Plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and selective, dual phosphodiesterase 3 and 4 (PDE3 and PDE4) inhibitor. This dual inhibition enables it to act as a bronchodilator and a non-steroidal anti-inflammatory agent . It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
15.72
USD
Average target price
33.86
USD
Spread / Average Target
+115.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.93% | 1.27B | |
| +2.49% | 96.73B | |
| -0.35% | 21.31B | |
| -16.61% | 21.21B | |
| -5.20% | 18.79B | |
| -42.14% | 16.37B | |
| -27.40% | 13.68B | |
| +1.44% | 13.44B | |
| +21.29% | 10.98B | |
| -21.79% | 8.56B |
- Stock Market
- Equities
- VRNA Stock
- News Verona Pharma plc
- Transcript : Verona Pharma plc, Q3 2022 Earnings Call, Nov 09, 2022
